Skyrizi from AbbVie Inc. - clear-skin data and tripled indications

Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-22, 21:36. Details in the imprint.

Skyrizi from AbbVie Inc. is the kind of drug name you now hear whispered in dermatology waiting rooms, while patients roll up their sleeves and quietly check the plaques on their forearms. The biologic has moved from newcomer to everyday workhorse, especially for people who have tried creams, pills and light therapy without relief. You can almost feel the relief when a skin that once itched and flaked now feels smooth again.

What Skyrizi is made for

Skyrizi is a humanized monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), a cytokine that drives inflammation in several immune-mediated diseases. It is approved for moderate-to-severe plaque psoriasis, active psoriatic arthritis and Crohn's disease in adults in major markets. In Europe and the US, regulators have framed it as an option for patients who are candidates for systemic therapy or phototherapy and have not responded adequately to conventional treatments.

In psoriasis, dermatologists often use Skyrizi when topical therapies and older systemic drugs such as methotrexate or cyclosporine have not delivered the desired skin clearance. Rheumatologists, in turn, plug it into treatment algorithms for psoriatic arthritis when joint pain and stiffness persist despite non-biologic disease-modifying drugs. Gastroenterologists use it in adults with moderately to severely active Crohn's disease who have had an inadequate response, lost response, or were intolerant to conventional or biologic therapy.

Dosing that fits real life

One reason Skyrizi has gained traction is its dosing rhythm. For plaque psoriasis, after two starter doses at week 0 and week 4, maintenance becomes one subcutaneous injection every 12 weeks, a schedule that many patients find less intrusive than monthly shots. In psoriatic arthritis, Skyrizi uses a similar 150 mg subcutaneous dose every 12 weeks after initiation, either alone or with conventional disease-modifying antirheumatic drugs.

Crohn's disease is different: treatment starts with a weight-based intravenous induction regimen, followed by subcutaneous maintenance dosing every eight weeks using an on-body injector or prefilled syringe. For a working parent juggling infusions and work, this pattern means a more intensive start, then a relatively quiet maintenance phase where the injection fits into a calendar reminder rather than dominating the month.

Clear-skin data and treat-to-target

AbbVie executive vice president and chief scientific officer Dr. Tom Hudson has repeatedly highlighted Skyrizi's "clear skin" profile as a core selling point, pointing to long-term trial data where a high proportion of patients maintain PASI 90 or PASI 100 responses over years of therapy. Long-term extension studies in plaque psoriasis have shown that many patients who reach high levels of skin clearance at week 16 or 52 maintain those responses through year three, with sustained improvements in Dermatology Life Quality Index scores. For someone who has worn long sleeves for years, the sight of nearly clear skin in the mirror becomes a daily reminder that the drug is doing its job.

In Crohn's disease, phase 3 trials such as ADVANCE and MOTIVATE have demonstrated that Skyrizi induces and maintains clinical remission and endoscopic response, including in difficult-to-treat patients who previously failed biologics. Endoscopic endpoints matter because they track mucosal healing rather than just symptom relief, and regulators in both the US and EU have cited these data when approving the indication.

Side effects and what patients notice

No biologic is free of risk, and Skyrizi is no exception. The most common side effects in psoriasis and psoriatic arthritis include upper respiratory infections, headache, fatigue, injection site reactions and tinea infections, while Crohn's patients also see nausea and abdominal pain in the label. Serious infections are a concern with all systemic immunomodulators, and prescribers screen patients for tuberculosis and other latent infections before initiation.

In practical terms, patients often report the injection itself as a relatively quiet experience, with a brief cold sting from the prefilled syringe or on-body injector followed by little irritation. Nurses in infusion centers describe Skyrizi patients as "in and out" once they are familiar with the induction schedule, especially compared with regimens that require more frequent hospital visits.

Pricing, access and home markets

Like other biologics, Skyrizi carries a high list price in the US, with annual treatment costs for psoriasis and psoriatic arthritis typically in the tens of thousands of dollars before rebates and discounts negotiated with insurers. In Europe, list prices tend to be lower but still significant, with national health systems and regional payers using treatment guidelines and prior authorization to manage budgets. AbbVie emphasizes patient support programs and copay assistance on its patient-facing materials, particularly in the US, where out-of-pocket costs can otherwise be a barrier to adherence.

For German readers, Skyrizi is marketed in the EU through AbbVie affiliates and is available via specialist dermatology, rheumatology and gastroenterology centers, subject to statutory health insurance rules and regional formularies. In the US, distribution runs primarily through specialty pharmacies and hospital systems, reflecting cold-chain requirements and the need for coordinated monitoring in complex immunology patients.

Where Skyrizi sits in AbbVie’s strategy

Skyrizi is one of the pillars of AbbVie's strategy to replace revenue from its aging bestseller Humira, alongside the JAK inhibitor Rinvoq. The company has guided for combined Skyrizi and Rinvoq sales to exceed previous Humira peak global sales later this decade, underscoring how central these drugs are to AbbVie's growth plan. In recent investor presentations, chief executive Richard A. Gonzalez has described Skyrizi as a "foundational" product in dermatology and gastroenterology, with room to grow in earlier lines of therapy and potentially additional indications.

Analysts follow prescription trends closely, including new-to-brand prescriptions and total prescriptions in psoriasis and Crohn's, to gauge the trajectory of Skyrizi’s market share in crowded biologic classes. Competitors include IL-23 inhibitors from other large pharma groups, as well as IL-17 blockers and TNF inhibitors that have long dominated rheumatology and dermatology. For patients and doctors, the choice often turns on details: dosing intervals, perceived speed of response and the weight of long-term safety data.

Company context and one stock note

For AbbVie, Skyrizi demonstrates that the company can move beyond dependence on a single blockbuster and build a diversified immunology franchise spanning skin, joints and gut. It ties directly into recent deals in immunology and inflammation, where management continues to add pipeline depth. Net-net, AbbVie shares (ISIN US00287Y1091) trade primarily on the New York Stock Exchange in US dollars, and Skyrizi’s performance remains a key factor for how investors view the company’s medium-term earnings power.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.